Phase II Study of the Histone Deacetylase Inhibitor MGCD0103 in Patients with Previously Treated Chronic Lymphocytic Leukemia

MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre-clinical activity in chronic lymphocytic leukaemia (CLL). A phase II clinical trial was performed, starting at a dose of 85 mg/day, three times per week. Dose escalation to 110 mg or the addition of ritu...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Blum, Kristie A., Advani, Anjani, Fernandez, Louis, Van Der Jagt, Richard, Brandwein, Joseph, Kambhampati, Suman, Kassis, Jeannine, Davis, Melanie, Bonfils, Claire, Dubay, Marja, Dumouchel, Julie, Drouin, Michel, Lucas, David M., Martell, Robert E., Byrd, John C.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2009
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2779118/
https://ncbi.nlm.nih.gov/pubmed/19747365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07881.x
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items